GPX4 and neoplasm: IHC staining and WB in xenograft tumor tissues revealed lower NRF2 and GPX4 expressions in the CLDN6 overexpression and sorafenib-treated CLDN6 overexpression groups compared to controls (Fig. 6D and E).